Repaglinide

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Repaglinide

Examples of brand names: NovoNorm [EU/DE]

ATC code: A10BX02

Main use (for orientation): Type 2 diabetes

Documented research summary

The static model PMID35115300 predicts a maximum 1.6-fold repaglinide AUC with CBD 700 mg; this is not a measured human drug–drug interaction. This model is the only direct result identified in the search.

Uncertainties and limitations

PMC11022902 could not be accessed; abstract/primary metadata read, no claim of full-text access.

Not to be used as a dosing recommendation.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

CBD – theoretical plausibility

Finding ID: B0398

Type of result: Model prediction, not a human finding

Observation: A maximum repaglinide AUC ratio of 1.6 was predicted for oral CBD 700 mg.

Mechanism: CYP inhibition; exposure prediction

Study type: Mechanistic static in vitro-to-in vivo model

Context studied: Model based on in vitro CYP data, with no participants experimentally receiving a repaglinide–CBD combination.

Clinical interpretation: Interpret within the stated study context; no independent dosage or treatment recommendation.

Limitations and uncertainties: Based on the abstract; model assumptions and unbound concentrations limit transferability. No measured hypoglycaemia or human AUC.

Original sources for this finding: Comprehensive Predictions of Cytochrome P450 (P450)-Mediated In Vivo Cannabinoid-Drug Interactions Based on Reversible and Time-Dependent P450 Inhibition in Human Liver Microsomes. [BMED35115300]

References and access status

[RLABEL_D0247] Repaglinid – DailyMed Produktkennzeichnung

Original source / bibliographic reference

Authors: Regulatory product information; respective marketing authorisation holder

Year: 2025

Source type: Product information / SmPC / US Prescribing Information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[BMED35115300] Comprehensive Predictions of Cytochrome P450 (P450)-Mediated In Vivo Cannabinoid-Drug Interactions Based on Reversible and Time-Dependent P450 Inhibition in Human Liver Microsomes.

Original source / bibliographic reference

Authors: Bansal S, Paine MF, Unadkat JD.

Year: 2022

Source type: Primary publication; abstract reviewed

DOI: 10.1124/dmd.121.000734

PMID: 35115300

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

PubMed Central – archived text

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility